Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 4, 2004, Pages 329-336

  Zamboni, William C ^a,b,c   Gervais, Anne C ^c   Egorin, Merrill J ^b,c   Schellens, Jan H M ^d   Zuhowski, Elleanor G ^c   Pluim, Dick ^d   Joseph, Erin ^c   Hamburger, Deborah R ^c   Working, Peter K ^e   Colbern, Gail ^e   Tonda, Margaret E ^e   Potter, Douglas M ^c   Eiseman, Julie L ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e ALZA CORPORATION   (United States)

Author keywords

Cisplatin; Microdialysis; Pharmacokinetics; SPI 077; STEALTH liposomes; Tumor

Indexed keywords

CISPLATIN; LIPOSOME; SPI 077 B 103;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DNA BINDING; DRUG TUMOR LEVEL; FEMALE; MELANOMA; MICRODIALYSIS; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CISPLATIN; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; INJECTIONS, INTRAVENOUS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICRODIALYSIS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 12144290727     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0719-4     Document Type: Article

References (48)

1. Dorr RT, Von Hoff DD (1993) Cisplatin monograph, 2nd ed. In: Dorr RT, Von Hoff DD (eds) Cancer chemotherapy handbook. Appleton and Lange, New York, p 286
2. Harrington KJ, Lewanski CR. Northcote AD, Whittaker J, Wellbank H, Vile RG, Peters AM, Stewart JS (2001) Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 12:493
3. DeMario MD, Vogelzang NJ, Janisch L, Tonda M. Amantes MA, Pendyala L, Ratain MJ (1998) A phase I study of liposome-formulated cisplatin (SPI-077) given every 3 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 17:883
4. Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, Yule SM, Morland B, Estlin EJ, Hale JP, Pearson AD, Welbank H, Boddy AV (2001) A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 84:1029
5. Schellens JHM, Meerum Terwogt J, Groenewegen G, Blijham GH, Ten Bokkel Huinink WW, Swart M, Maliepaard M, Floot B, Welbank H, Beijnen JH (1998) Phase I and pharmacologic study of SPI-77, a novel STEALTH liposomal encapsulated formulation of cisplatin (CDDP). Proc Am Assoc Cancer Res 39:2218
6. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1
7. Gerad H, Egorin MJ, Whitacre M, Van Echo DA, Aisner J (1983) Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia. Cancer Chemother Pharmacol 11:162
8. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1- cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432
9. Allen TM, Stuart DD (1998) Liposomal pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes. In: Janoff AS (ed) Liposomes: rational design. Marcel Dekker. New York, p 63
10. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171
11. Pluim D, Maliepaard M, van Waardenburg RC, Beijnen JH, Schellens JH (1999) 32P-postlabeling assay for the quantification of the major platinum-DNA adducts. Anal Biochem 275:30
12. Reed E, Saurhoff S, Poirier MC (1998) Quantitation of platinum-DNA binding after therapeutic levels of drug exposure: a novel use of graphite furnace spectrometry. Atom Spectrosc 3:93
13. Johansen MJ, Newman RA, Madden T (1997) The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy 17:464
14. Kehr J (1993) A survey on quantitative microdialysis: theoretical models and practical implications. J Neurosci Methods 48:251
15. Zamboni WC, Houghton PJ. Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF (1999) Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43:269
16. Muller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blochl-Daum B (1997) 5-Fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 57:2598
17. Blochl-Daum B, Muller M, Meisinger V, Eichler HG, Fassolt A, Pehamberger H (1996) Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer 73:920
18. Muller M, Schmid R, Georgopoulos A, Buxbaum A, Wasicek C, Eichler HG (1995) Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 57:371
19. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL (2002) Inter-and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res 8:2992
20. Conley BA, Ramsland TS, Sentz DL, Wu S, Rosen DM, Wollman M, Eiseman JL (1999) Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother Pharmacol 43:183
21. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115
22. Zamboni WC, Luftner DI, Egorin MJ, Schweigert M, Sezer O, Richter T, Natale JJ, Possinger K (2001) The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Ann Oncol 12:119
23. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
24. Hirsch RP, Riegelman RK (1992) Statistical first aid: interpretation of health research data. Blackwell Scientific, Boston
25. Rosner B (2000) Fundamentals of biostatistics, 5th edn. Duxbury, Pacific Grove, CA
26. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, Stewart JS (2001) Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7:243
27. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JS (2000) Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer 83:232
28. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Abra RM, Uster PS, Peters AM, Stewart JS (2000) Influence of tumour size on uptake of (111)In-DTPA- labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer 83:684
29. Northfelt DW (1994) STEALTH liposomal doxorubicin (SLD) delivers more DOX to AIDS-Kaposi's sarcoma lesions than to normal skin. Proc Am Soc Clin Oncol 13:51
30. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16:683
31. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du MC, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16:2445
32. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987
33. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin FJ (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711
34. Peleg-Shulman T, Gibson D, Cohen R, Abra R, Barenholz Y (2001) Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim Biophys Acta 1510:278
35. Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E, Saville R, Weng S, Luzzio M, Uster P, Amantea M, Working PK (1998) Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin Cancer Res 4:3077
36. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133
37. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88:11460
38. Drumond DC, Meyer O, Hong K (1991) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumor. Pharmacol Rev 51:692
39. Working PK, Newman MS, Huang SK (1994) Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in STEALTH liposomes. Liposome Res 46:667
40. Jain RK (1996) Delivery of molecular medicine to solid tumors. Science 271:1079
41. Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG (2001) Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 45:2623
42. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD (2000) Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60:3389
43. Verschraegen CF, Gilbert BE, Huaringa AJ, Newman R, Harris N, Leyva FJ, Keus L, Campbell K, Nelson-Taylor T, Knight V (2000) Feasibility, phase I, and pharmacologic study of aerosolized 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann N Y Acad Sci 922:352
44. Desjardins JP, Abbott EA, Emerson DL, Tomkinson BE, Leray JD, Brown EN, Hamilton M, Dihel L, Ptaszynski M, Bendele RA, Richardson FC (2001) Biodistribution of NX211, liposomal lurtotecan, in tumor bearing mice. Anticancer Drugs 12:235
45. Sharma A, Straubinger RM, Ojima I, Bernacki RJ (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 84:1400
46. Ducan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, Searle F (2001) Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from laboratory to clinic. J Control Release 74:135
47. Sharma A, Straubinger RM, Ojima I, Bernacki RJ (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 84:1400-1404
48. Ducan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, Searle F (2000) Polymer drug conjugates, PDEPT and PELT: basic principles for design and transfer from laboratory to clinic. J Control Release 74:135-146